Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus

• Published in: Srpski arhiv za celokupno lekarstvo Vol. 142; no. 7-8; pp. 431 - 436
• Main Authors: Zivkovic, Valentina, Stankovic, Aleksandra, Cvetkovic, Tatjana, Mitic, Branka, Kostic, Svetislav, Nedovic, Jovan, Stamenkovic, Bojana
• Format: Journal Article
• Language: English
• Published: Serbia Serbian Medical Society 01.07.2014
• Subjects: Adult; anti-C1qantibodies; anti-dsDNA antibodies; anti-nucleosome antibodies; Autoantibodies - blood; Biomarkers - blood; Complement C1q - immunology; DNA - immunology; Female; Humans; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - immunology; lupus nephritis; Lupus Nephritis - diagnosis; Lupus Nephritis - immunology; Male; Middle Aged; Nucleosomes - immunology; Sensitivity and Specificity; SLEDAI; systemic lupus erythematosus
• ISSN: 0370-8179; 2406-0895
• DOI: 10.2298/SARH1408431Z

In spite of the growing number of reports on the study of anti-nucleosome and anti-C1q antibodies, there are still controversies on their significance as disease activity markers in patients with systemic lupus erythematosus (SLE) and their use in everyday clinical practice. Our aim was to assess the presence of anti-dsDNA, anti-nucleosome and anti-C1q antibodies in SLE patients, as well as to establish their sensitivity, specificity, positive and negative predictive value, and their correlation with SLE and lupus nephritis clinical activity. The study enrolled 85 patients aged 45.3 +/- 9.7 years on the average, with SLE of average duration 10.37 +/- 7.99 years, hospitalized at the Institute,,Niska Banja" during 2011, and 30 healthy individuals as controls. Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). In all examinees the levels of anti-dsDNA, anti-nucleosome and anti-C1q antibodies were measured using the ELISA method with Alegria Test Strips Orgentec (Germany). Patients with active lupus nephritis had a higher presence of anti-C1q antibodies and higher co-positivity of anti-dsDNA, anti-nucleosome, and anti-C1q antibodies compared to those with inactive lupus nephritis (77.77% vs. 21.74%; p < 0.01). SLE patients with SLEDAI > or = 11 had a higher presence of antinucleosome (93.75% vs. 64.15%; p < 0.01) and anti-C1q antibodies (46.87% vs. 22.64%; p<0.05), as well as a higher mean level of anti-nucleosome antibodies (107.79 +/- 83.46 U/ml vs. 57.81 +/- 63.15 U/ml; p < 0.05), compared to those with SLEDAI of 0-10. There was a positive correlation between the SLEDAI and the level of anti-dsDNA (r=0.290; p<0.01), anti-nucleosome (r = 0.443; p < 0.001), and anti-C1q antibodies (r = 0.382; p < 0.001). Only anti-C1q antibodies demonstrated correlation with proteinuria (r = 0.445; p < 0.001). Anti-nucleosome and anti-C1q antibodies demonstrated association with SLE and lupus nephritis activity, suggesting their potential usefulness in making predictions about lupus nephritis and assessment of disease activity.